News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SINO BIOPHARMACEUTICAL (01177.HK)'s Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial
SINO BIOPHARMACEUTICAL (01177.HK) announced that Vetricotobat Monoclonal Antibody (CLDN18.2 ADC), a Class 1 innovative drug independently developed by Lixin Pharmaceutical, a wholl...
Reset
Send
The window will close in 5 seconds
SINO BIOPHARMACEUTICAL (01177.HK)'s Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial
Close
Recommend
17
Positive
28
Negative
12
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

SINO BIOPHARMACEUTICAL (01177.HK)  -0.130 (-2.185%)    Short selling $90.75M; Ratio 22.538%   announced that Vetricotobat Monoclonal Antibody (CLDN18.2 ADC), a Class 1 innovative drug independently developed by Lixin Pharmaceutical, a wholly-owned subsidiary of the Group, is undergoing a Phase III pivotal clinical trial (LM302-03-201) in combination with a PD-1 monoclonal antibody as first-line treatment for patients with CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (GC/GEJ). The first patient has been successfully enrolled.

This study is the second Phase III clinical trial conducted for LM-302 and is also the worlds first Phase III clinical trial of a CLDN18.2 ADC therapy using a chemotherapy-free regimen for first-line treatment of gastric cancer. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-21 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.